Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

236 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Current evidence in the field of the management with TNF-α inhibitors in psoriatic arthritis and concomitant hepatitis C virus infection.
Caso F, Cantarini L, Morisco F, Del Puente A, Ramonda R, Fiocco U, Lubrano E, Peluso R, Caso P, Galeazzi M, Punzi L, Scarpa R, Costa L. Caso F, et al. Among authors: lubrano e. Expert Opin Biol Ther. 2015 May;15(5):641-50. doi: 10.1517/14712598.2015.1011616. Epub 2015 Feb 4. Expert Opin Biol Ther. 2015. PMID: 25652590 Review.
Psoriatic arthritis (PA): a harmless disease?
Scarpa R, della Valle G, Lubrano E, di Girolamo C, Del Puente A, Oriente P. Scarpa R, et al. Among authors: lubrano e. Br J Rheumatol. 1992 Mar;31(3):210-1. doi: 10.1093/rheumatology/31.3.210. Br J Rheumatol. 1992. PMID: 1540794 No abstract available.
A rare enthesopathy in psoriatic oligoarthritis.
Scarpa R, Ames PR, della Valle G, Lubrano E, Oriente P. Scarpa R, et al. Among authors: lubrano e. Acta Derm Venereol Suppl (Stockh). 1994;186:74-5. Acta Derm Venereol Suppl (Stockh). 1994. PMID: 8073846
The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy.
Olivieri I, de Portu S, Salvarani C, Cauli A, Lubrano E, Spadaro A, Cantini F, Cutro MS, Mathieu A, Matucci-Cerinic M, Pappone N, Punzi L, Scarpa R, Mantovani LG; PACE working group. Olivieri I, et al. Among authors: lubrano e. Rheumatology (Oxford). 2008 Nov;47(11):1664-70. doi: 10.1093/rheumatology/ken320. Epub 2008 Aug 24. Rheumatology (Oxford). 2008. PMID: 18725374 Free PMC article.
Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs.
Atteno M, Peluso R, Costa L, Padula S, Iervolino S, Caso F, Sanduzzi A, Lubrano E, Del Puente A, Scarpa R. Atteno M, et al. Among authors: lubrano e. Clin Rheumatol. 2010 Apr;29(4):399-403. doi: 10.1007/s10067-009-1340-7. Clin Rheumatol. 2010. PMID: 20066450 Clinical Trial.
Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis: a 4-year study.
Spadaro A, Punzi L, Marchesoni A, Lubrano E, Mathieu A, Cantini F, Olivieri I, Salvarani C, Scarpa R, Scrivo R, Ramonda R, Porru G, D'Angelo S, Catanoso M, Atteno M, Valesini G. Spadaro A, et al. Among authors: lubrano e. Rheumatology (Oxford). 2010 Jun;49(6):1107-11. doi: 10.1093/rheumatology/keq008. Epub 2010 Mar 11. Rheumatology (Oxford). 2010. PMID: 20223813
Emerging drugs for psoriatic arthritis.
Olivieri I, D'Angelo S, Palazzi C, Lubrano E, Leccese P. Olivieri I, et al. Among authors: lubrano e. Expert Opin Emerg Drugs. 2010 Sep;15(3):399-414. doi: 10.1517/14728214.2010.497139. Expert Opin Emerg Drugs. 2010. PMID: 20528612 Review.
236 results